Tyrosine kinase: Implications in tumorigenesis and new avenues for cancer treatment;Tyrosine kinase: Implications en pathologie tumorale et perspectives therapeutiques

Revue de Medecine Interne

Volumn 19, Issue 5, 1998, Pages 366-372

  Peyrade, F ^a,d   Taillan, B ^a   Lebrun, C ^b   Baron, V ^c   Dujardin, P ^a  

^a University of Côte d'Azur   (France)

^b PASTEUR HOSPITAL   (France)

^c INSERM   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Cancer; Oncogene; Tyrosine kinase; Tyrphostin

Indexed keywords

BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN;

CANCER; CARCINOGENESIS; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032079032     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(98)80114-8     Document Type: Article

References (15)

1. Chardin P. Protéine Ras et transmission des signaux mitogènes. Méd/Sci 1994; 10 : 657-64
2. Bos JL. Ras oncogene in human cancer. A review. Cancer Res 1989 ; 494 : 682-9
3. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Sotloff S. Oncogenes and signal transduction. Cell 1991 ; 64 : 281-302
4. Shuai K, Ziemeck A, Wilks A, Harpur A, Sadowski H, Gilman MZ et al . Polypeptide signalling to the nucleus through the phosphorylation of JAK and stat protein. Nature 1993 ; 366 : 580-5
5. Levitzki A, Gazit Z. Tyrosine kinase inhibition: an approach to drug developpement. Science 1995 ; 267 : 1782-8
6. Chomel JC, Guilhot F, Tanzer J, Kitzis A. Mécanismes d'action oncogénique de Bcr-abl dans la leucémie myéloïde chronique. Méd/Sci 1995 ; 11 : 1669-77
7. Cance WG, Liu ET. Protein kinases in human breast cancer. Breast Cancer Res Treat 1995 ; 35 : 105-14
8. Lebrun C, Frenay M. Le récepteur de 1'epidermal growth factor. In: Biologie des tumeurs cérébrales gliales. Tome II. Paris: Servier; 1996. p 179
9. Salomon DS, Brandt R, Ciardello F, Normann R. Epidermal growth factor related peptides and their receptors in human malignancies. Critical reviews. Oncol Hematol 1995 ; 19 : 183-232
10. Guilhot, F. Diagnostic et traitement des hémopathies comportant un réarrangement Bcr-abl. Hématologie 1995 ; 2 : 133-44
11. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of Bcr-abl transcript in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993 ; 82 : 1929-36
12. Tien HF, Wang CH, Chen YC. Chromosom and Bcr rearrangement in chronic myelogenous leukemia and their correlation with clinical states and prognosis of the disease. Br J Hematol 1990; 75 : 469
13. Myers C, Cooper M, La Rocca R, Mac Lellan MW, Weiss G, Choyke P et al . Suramin: a novel growth hormon antagonist with activity i hormone-refractory metastatic prostate cancer. J Clin Oncol 1992 ; 10 : 881-9
14. Vanumerssen L, Ness E, Goldstein DJ, Disbrow G, Metlay L, Hawver AL et al . A phase I trial of SU101 in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol 1997 ; 14: 16-21la
15. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L. Phase study of weekly intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody in patients with HER-2/neu -overexpressing metastatic breast cancer. J Clin Oncol 1996 ; 14 : 737-44